Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 813, doi. 10.1007/s11883-022-01055-1
- By:
- Publication type:
- Article
Works matching IS 15233804 AND DT 2022 AND VI 24 AND IP 10
Results: 7
1
2
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 821, doi. 10.1007/s11883-022-01057-z
- By:
- Publication type:
- Article
3
Inclisiran: How Widely and When Should We Use It?
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 803, doi. 10.1007/s11883-022-01056-0
- By:
- Publication type:
- Article
4
Bempedoic Acid: for Whom and When.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 791, doi. 10.1007/s11883-022-01054-2
- By:
- Publication type:
- Article
5
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 779, doi. 10.1007/s11883-022-01053-3
- By:
- Publication type:
- Article
6
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 767, doi. 10.1007/s11883-022-01052-4
- By:
- Publication type:
- Article
7
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 10, p. 755, doi. 10.1007/s11883-022-01051-5
- By:
- Publication type:
- Article